A more affordable drug for neuroendocrine tumors diagnostics passing preclinical tests
Share

IMAGE: TPU scientists Mekhman Yusubov, Alexey Pestryakov, and Roman Surmenev at the press conference (From the left to the right ). view more 

Credit: Tomsk Polytechnic University

Leading researchers, physicists, and materials scientists of the Research School of Chemistry & Applied Biomedical Sciences of Tomsk Polytechnic University are engaged in the creation of diagnostic and therapeutic drugs, in particular for oncology. The Director of the School Mekhman Yusubov stated at the press conference on 27 April 2018 that one of the developed diagnostic drugs is now passing preclinical tests. The tests should be completed by the end of 2018. This is a drug for the diagnostics of neuroendocrine tumors, which was obtained together with physicists and oncologists.

‘Diagnostic drugs should be affordable therefore it is necessary to reduce their cost.

Moscow-based company Pharm-Syntez has been already producing a drug for diagnostics of neuroendocrine tumors. They use the expensive radionuclide indium-111 (111In), we replaced it with more affordable and cheaper radionuclide technetium. The challenge was how to combine antigen and technetium. For this, we synthesized a special linker. Based on the results of the tests Pharm-Sintez is ready to produce a new technetium-based drug,’ clarified the director of the school.

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD